Collin Hovinga, PharmD, MS, FCCP
Collin Hovinga, PharmD, MS, FCCP, serves as Vice President of the Rare and Orphan Disease Programs at the Critical Path Institute overseeing C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform and the Critical Path for Rare Neurodegenerative Diseases public-private partnership. Dr. Hovinga completed his Bachelor of Science Degree in Biology and Doctor of Pharmacy degrees from Creighton University in Omaha, Nebraska. After which he pursued a Residency and Fellowship in Pediatric Pharmacotherapy with emphasis in Pediatric Neuroscience at the University of Tennessee, Memphis, LeBonheur Children’s Medical Center. He has had a Fellowship at the Food and Drug Administration Office of Clinical Pharmacology and a Masters of Epidemiology from the University of Tennessee Health Science Center. Dr. Hovinga has been active in studying factors that influence the efficacy, safety and the pharmacology of antiepileptic drugs in children, patient adherence to medications, and acute seizure management. Dr. Hovinga is recognized as an expert in neuropharmacology.